Clinical trial
A Prospective, Multi-centric, Phase Ⅲ, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine (AG) Versus Oxaliplatin Plus Folinic Acid and Fluorouracil (OFF) for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection
NCT02506842 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multi-centric, Phase Ⅲ, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine (AG) Versus Oxaliplatin Plus Folinic Acid and Fluorouracil (OFF) for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection
- Lead sponsor
- Fudan University
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- June 30, 2015
- Completion date
- June 30, 2019
- Enrollment
- 300 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
stage Ⅰa pancreatic cancer, stage Ⅰb pancreatic cancer, stage Ⅱa pancreatic cancer, stage Ⅱb pancreatic cancer